Abstract:Objective To investigate the expression of survivin in human sacral chordoma tissues,so as to provide the oretical basis for prognosis and molecular targeted therapy.Methods Through the inclusion and exclusion criteria for screening and follow-up to the hospitalized patients from January 2000 to July 2010,the complete medical records,tu mor tissue paraffin block specimens of 30 cases and tumor adjacent normal tissue in 10 cases are obtained;Expres sions of survivin and CD34 was detected in 30 cases of human sacral chordoma tissues and 10 normal notochord tis sues through SP immunohistochemistry,with micro-vessel in chordoma tissues marked with CD34;Statistical analysis was used to tell the difference of survivin expression between the sacral chordoma tissue and normal notochord tissues;Statistical analysis was used to tell the difference of MVD between the sacral chordoma tissue and normal notochord tissues and that between the positive and negative expression of survivin and VEGF in the sacral chordoma tissue;Whether the expression of survivin in tumor tissue strength was related to gender,age,tumor size,tumor location,and tumor recurrence was included;single factor in the Kaplan-Meier analysis of recurrence results was included and CDFS curve was drawn,and also Log-Rank method was used for hypothesis testing.Results ①The positive expression rate of survivin in chordoma was 70.0%,which was significantly higher than its in the normal notochord tissues(P < 0.05);the MVD marked by CD34 was(27.2±10.70)/mm2 in the chordoma tissues much higher than that(8.90 ±3.11)/ mm2 in the normal notochord tissue,there was significant difference(P < 0.05).②The MVD in the positive expression group of survivin was(30.71±10.35)/mm2.It was significantly higher than that in the negative expression group(19.00 ± 6.25)/mm2(P < 0.05).③The positive rate of survivin was correlated significantly with tumor invasion of the surround ing muscle and recurrence(P < 0.05);④The log-rank the postoperative CDFS showed a significant difference between survivin positive and negative groups(P = 0.005).Conclusion ①The expression rate of survivin was high in the sacral chordoma tissues,the vessels of the survivin-positive was richer than those of the survivin-negative in sacral chordo ma,survivin expression was positively correlated in the angiogenesis process.②Survivin was one of independent predictors of postoperative CDFS period in sacral chordoma patients.The results of expression of survivin in sacral chor doma provided a theoretical basis on prognosis of sacral chordoma and targeted therapies.

High Expression of Survivin in Sacral Chordoma

Expression of survivin in sacral chordoma and its clinical significance

Correlation Between Expression of Survivin and Cysteinyl Aspartate-Specific Protease and Apoptosis in Sacral Chordoma

Expression of Survivin and VEGF in Sacral Chordoma Provides Potential Targets for Therapy

Study on the Correlation Between the Expression and the Angiogenesis of Survivin and VEGF in Sacral Chordoma

High expression of SPHK1 in sacral chordoma and association with patients’ poor prognosis

Association of Telomerase Expression with Recurrence of Sacral Chordoma.

Prognostic Factors of Sacral Chordoma after Surgical Therapy: a Study of 36 Patients.

Expression of Survivin and Its Correlation with Expression of Bcl-2 and P53 in Colorectal Adenocarcinoma

Analysis of Recurrent Factors of Sacral Chordoma

Overexpression of CD40 in Sacral Chordomas and Its Correlation with Low Tumor Recurrence

High expression of Sam68 in sacral chordomas is associated with worse clinical outcomes.

Clinical treatment of sacral chordoma

The clinical outcome of recurrent sacral chordoma with further surgical treatment.

Recurrence and Survival Factors Analysis of 171 Cases of Sacral Chordoma in a Single Institute.

Expression of Insulin-Like Growth Factor Ii Mrna-Binding Protein 3 (imp3) in Sacral Chordoma

Survival Analysis of Patients with Spinal Chordomas.

Analysis of Risk Factors for Recurrence after the Resection of Sacral Chordoma Combined with Embolization.

Clinical Outcome after Surgical Treatment of Sacral Chordomas: A Single-Center Retrospective Cohort of 27 Patients

Analysis of Clinicopathologic Features and Immunophenotype in 55 Patients with Chordoma

Clinical Characteristics and Predisposing Factors of Lung Metastasis in Sacral Chordoma: a Cross-Sectional Cohort Study of 221 Cases